Thermo Fisher (TMO) Stock Analysis
NYQ · Healthcare · Diagnostics & Research
$668.59
-5.13 (-0.76%)
TMO Interactive Price Chart & Trading Signals
TMO Stock Snapshot — Valuation, Risk & Technical Signals
TMO Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
มูลค่าตลาด
$247.21B
P/E
36.02
Forward P/E
24.27
PEG
2.01
P/B
4.69
EPS
$18.56
เงินปันผล
0.28%
ช่วง 52 สัปดาห์
$435.27 – $682.98
Beta
0.85
ปริมาณ
0.0M
ROE
13.5%
อัตรากำไร
15.0%
การเติบโตของรายได้
10.5%
อัตรากำไรขั้นต้น
41.0%
EV/EBITDA
24.55
เป้าหมายนักวิเคราะห์
$653.11
The trailing price-to-earnings ratio stands at 36.0x. Forward P/E of 24.3x implies earnings expansion expected. Price-to-book is 4.69x. EV/EBITDA sits at 24.55x. Market capitalization is $247.21B. Revenue is growing at 10.5% on a trailing basis. Earnings are expanding at 9.4%. Profit margins are 15.0%. Return on equity is 13.5%. Beta of 0.85 indicates market-average volatility.
Analyst Consensus
คำแนะนำ
Buy
เป้าหมายต่ำ
$520.00
เป้าหมายเฉลี่ย
$653.11
เป้าหมายสูง
$780.00
จากนักวิเคราะห์ 27 คน
เกี่ยวกับ Thermo Fisher
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
TMO Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Thermo Fisher Scientific Inc. (TMO) trades above our multi-model fair value estimate of $289.26 by approximately 56.7%. Trailing P/E: 36.0x. Profitability signals include profit margin of 15.0% and return on equity of 13.5%. Recent growth metrics show revenue growth of 10.5% and earnings growth of 9.4%. Risk profile: beta of 0.85. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 36.0x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 10.5%
Revenue is outpacing the market.
Valuation Snapshot
Thermo Fisher Scientific Inc. (TMO) trades above our multi-model fair value estimate of $289.26 by approximately 56.7%. The trailing price-to-earnings ratio stands at 36.0x. Forward P/E of 24.3x suggests earnings compression ahead. Price-to-sales is 5.3x. Price-to-book is 4.7x. EV/EBITDA sits at 24.6x. Market capitalization is $247.21B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 10.5% on a trailing basis. Earnings are expanding at 9.4%. Profit margins are 15.0%. Return on equity is 13.5%. Return on assets is 5.1%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.85 indicates market-average volatility. Net debt position is $38.48B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $653.11 implies 2.3% downside. Target range spans $520.00 to $780.00. 27 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
TMO Overvalued
Thermo Fisher Scientific Inc. (TMO) trades above our multi-model fair value estimate of $289.26 by approximately 56.7%.
Frequently Asked Questions
ValuationIs TMO stock overvalued right now?
ValuationWhat is TMO fair value based on current fundamentals?
RiskHow risky is TMO compared with other stocks?
GrowthIs TMO still growing?
AnalystWhat do analysts think about TMO?
DividendDoes TMO pay a dividend?
CatalystWhat could change the investment case for TMO?
Related Stocks
เกี่ยวกับผู้เขียน
Phasakorn Traklang (Peach) — ผู้ก่อตั้ง
ภาสกร ตรากลาง (พีช) เป็นผู้ก่อตั้ง QuantSoar และนักวิจัยการลงทุนเชิงปริมาณที่เชี่ยวชาญด้านการประเมินมูลค่าหุ้นหลายโมเดล การวิเคราะห์กระแสสถาบัน และการสร้างพอร์ตแบบเป็นระบบ เขาสร้างแพลตฟอร์มการเงินที่ขับเคลื่อนด้วยข้อมูลเพื่อให้บริการนักลงทุนรายย่อยทั่วโลก
เชื่อมต่อ LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
แหล่งที่มาข้อมูล: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub